Bristol-Myers Squibb Aktie News

These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue.

Chevron is an integrated energy company with an impressive yield and an impressive dividend history. Bristol Myers has a high yield, but the drugmaker is out of favor.

This article presents a diversified, fund-based portfolio targeting market-matching growth and a 6%+ income yield, with lower tech exposure than the S&P 500. The model portfolio, comprising 5 ETFs and 6 CEFs, emphasizes asset class diversification—spanning blue-chip dividends, tech, real estate, gold, materials, energy, and utilities. The portfolio presented uses ahands-off approach, and it is ...

Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase.

Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.

Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues to cover its dividend.